{{Drugbox
| verifiedrevid = 447387851
| IUPAC_name = ''N''-benzyl-3-(''N''-(pyridine-4-carbonyl)hydrazino)propanamide
| image =Nialamide.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|nialamide}}
| pregnancy_category =  
| legal_AU = S4
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51-12-7
| ATC_prefix = N06
| ATC_suffix = AF02
| PubChem = 4472
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04820
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4317
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = T2Q0RYM725
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07337
<!--Chemical data-->
| C=16 | H=18 | N=4 | O=2
| molecular_weight = 298.34 g/mol
| smiles = O=C(NNCCC(=O)NCc1ccccc1)c2ccncc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NOIIUHRQUVNIDD-UHFFFAOYSA-N
}}

'''Nialamide''' ('''Niamid''', '''Niamide''', '''Nuredal''', '''Surgex''') is a non-selective, [[irreversible inhibition|irreversible]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] class that was used as an [[antidepressant]].<ref name="Publishing2006">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935|date=1 December 2006|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref> It was withdrawn by [[Pfizer]] several decades ago due to the risk of [[hepatotoxicity]].<ref name="Gad2012">{{cite book|author=Shayne C. Gad|title=Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition|url=https://books.google.com/books?id=AHA2g-qq6WwC&pg=PA138|date=26 April 2012|publisher=CRC Press|isbn=978-1-4398-4567-7|pages=138–}}</ref><ref name="Shorter2008">{{cite book|author=Edward Shorter|title=Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry|url=https://books.google.com/books?id=8VaYF8pIPxgC&pg=PA137|date=28 September 2008|publisher=Oxford University Press|isbn=978-0-19-970933-5|pages=137–}}</ref>

The antiatherogenic activity of nialamide was used to design [[pyridinolcarbamate]].<ref>{{cite web|url=https://books.google.co.uk/books?id=a1bmCAAAQBAJ&pg=PA387#v=onepage&q&f=false|title=Hypolipidemic Agents|first1=W. L.|last1=Bencze|first2=M. E.|last2=Dempsey|first3=S.|last3=Eisenberg|first4=J. M.|last4=Felts|first5=I. D.|last5=Frantz|first6=R.|last6=Hess|first7=R. I.|last7=Levy|first8=T. A.|last8=Miettinen|first9=L. L.|last9=Rudel|first10=H. S.|last10=Sodhi|first11=W.|last11=Stäubli|first12=T.|last12=Zempl;&AAe;nyi|date=6 December 2012|publisher=Springer Science & Business Media|accessdate=3 October 2017|via=Google Books}}</ref>

==See also==
* [[Hydrazine (antidepressant)]]

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Monoamine metabolism modulators}}
{{Hydrazines}}

[[Category:Hepatotoxins]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Pyridines]]
[[Category:Hydrazides]]
[[Category:Propionamides]]
[[Category:Withdrawn drugs]]